AbCellera Biologics (ABCL) vs Enliven Therapeutics (ELVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 176.1% versus a gain of 113.9%. Over five years, ELVN leads with a +254.6% price change compared with -30.7% for ABCL. Enliven Therapeutics is the larger company by market cap ($3.42 billion vs $3.16 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | ELVN |
|---|---|---|
| Share price | $9.69 | $46.53 |
| Market cap | $3.16B | $3.42B |
| 1-day change | -7.45% | +0.26% |
| YTD return | +183.33% | +202.14% |
| 1-year return | +176.07% | +113.93% |
| 5-year return | -30.74% | +254.65% |
| EPS (TTM) | $-0.48 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | — |
| Revenue growth (YoY) | +160.56% | — |
| Net income (latest FY) | $-146.41M | $-103.69M |
| Operating margin | -288.98% | — |
| Net margin | -194.88% | — |
| 52-week high | $15.02 | $62.32 |
| 52-week low | $2.75 | $14.79 |
| Distance from 52-week high | -35.46% | -25.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.67% | +59.75% |
| Average volume | 4.34M | 1.36M |
| Shares outstanding | 326.62M | 73.60M |
| Employees | 562 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed ELVN by 62.1 percentage points over the past year.
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ABCL vs ELVN FAQ
Which is bigger, AbCellera Biologics or Enliven Therapeutics?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.42B compared with $3.16B for AbCellera Biologics (ABCL).
Which stock has performed better over the past year, ABCL or ELVN?
ABCL returned +176.07% over the past 12 months, compared with +113.93% for ELVN (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Enliven Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.